Business Context and Reporting Period
This Form 8-K Current Report was filed by BlueLinx Holdings Inc. on April 28, 2020, regarding an event that occurred on April 22, 2020. The filing addresses a regulatory notice from the New York Stock Exchange (NYSE) concerning the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses the following financial thresholds that triggered the regulatory action:
- Market Capitalization: The average global market capitalization over a consecutive 30 trading-day period was below $50 million.
- Stockholders' Equity: The last reported stockholders' equity was below $50 million.
- Cause: The decline in these metrics was attributed to the significant stock market decline triggered by the COVID-19 pandemic.
Material Changes
The primary material change reported is the receipt of a written notice from the NYSE on April 22, 2020, stating non-compliance with Section 802.01B of the NYSE Listed Company Manual. Prior to the pandemic-induced market decline, the Company's market capitalization was above the $50 million threshold.
Outlook, Risks, and Management Commentary
Management Action: On April 28, 2020, the Company submitted a plan to the NYSE outlining definitive actions to regain conformity with listing standards within an 18-month cure period.
Process and Risks:
- The NYSE has 45 days to review the plan.
- If accepted, the Company will be subject to ongoing monitoring for 18 months.
- If rejected, the Company will be subject to suspension and delisting procedures.
- Even if the plan is accepted, the NYSE retains the right to take accelerated delisting action if the stock trades at levels viewed as "abnormally low."
- The Company explicitly states it can provide no assurances that it will satisfy the steps to maintain its listing.
Current Status: The notice has no immediate impact on trading; shares continue to be listed and traded on the NYSE pending the outcome of the plan review.
Investor Verification Checklist
- Verify the NYSE's decision on the Company's 18-month compliance plan within the 45-day review window.
- Monitor the Company's stock price to ensure it does not trigger "abnormally low" trading thresholds during the cure period.
- Review subsequent filings for updates on the Company's stockholders' equity and market capitalization trends.
- Confirm whether the Company has filed any additional reports regarding liquidity or capital raising efforts to address the equity shortfall.